NCT04783428 2026-01-21
Tumor-induced Osteomalacia Disease Monitoring Program
Ultragenyx Pharmaceutical Inc
Active not recruiting
Clinical Trials
5 trialsNCT03775187 2025-03-05
Expanded Access to Burosumab
Kyowa Kirin Co., Ltd.
Available
NCT05357573 2024-07-09
Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Adult Chinese Patients With TIO
Kyowa Kirin Co., Ltd.
Phase 4 Completed
NCT02304367 2024-05-06
Study of Burosumab (KRN23) in Adults With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS)
Kyowa Kirin Co., Ltd.
Phase 2 Completed
NCT02722798 2022-09-06
A Study of KRN23 in Subjects With Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome
Kyowa Kirin Co., Ltd.
Phase 2 Completed